An observational study of response heterogeneity in children with attention deficit hyperactivity disorder following treatment switch to modified-release methylphenidate

BMC Psychiatry

Manfred Döpfner¹  Aribert Rothenberger²  Christopher Hautmann¹ 

[1]Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne, Robert-Koch-Str. 10, 50931 Cologne, Germany

[2]Department of Child and Adolescent Psychiatry, University Medicine Göttingen, von Sieboldstr 5, 37075 Göttingen, Germany

关键词: Trajectory;    Growth mixture modelling;    Modified-release MPH;    Methylphenidate;    ADHD;   

Others  :  1123974
DOI  :  10.1186/1471-244X-13-219

 received in 2013-01-25, accepted in 2013-08-22,  发布年份 2013

【 摘 要 】

Background

Methylphenidate (MPH) has been shown to be effective in the treatment of attention deficit hyperactivity disorder (ADHD) in children. The overall population of children and adolescents with ADHD may comprise distinct clusters of patients that differ in response to MPH. The aim of this analysis was to look for subgroups with different treatment trajectories and to identify their distinctive features.

Methods

OBSEER was a prospective, observational study examining the effectiveness and safety of once-daily modified-release MPH over 3 months in patients (aged 6–17 years) with ADHD under routine care. Assessments were carried out at baseline (Visit 1), after 1–3 weeks (Visit 2) and 6–12 weeks (Visit 3) after first use of once-daily modified-release MPH. Change in ADHD symptoms, as rated by parents and teachers, was examined post hoc in patients of the intent-to-treat-population (N = 822), using growth-mixture modelling to detect response trajectory groups after switching medication. Age, MPH dose at Visit 1 before medication switch, prescribed once-daily modified-release MPH dose at Visits 1 and 2, conduct problems and emotional symptoms were considered predictors of response subgroups.

Results

Assessing formal statistical criteria and usefulness of the models, a 4-class solution best fitted the data: after switching medication two response groups with severe symptoms at study start and subsequent substantial treatment effects, and two showing no or comparatively little treatment effect, one of which had severe and the other less severe symptoms at study start. Patient age, conduct problems and MPH dose at Visit 1 were predictors of inclusion in subgroups.

Conclusions

Older children and children with few conduct problems were more likely to be members of a patient cluster with fewer symptoms at study start. Children with a low MPH dose before medication switch had a higher chance of being in the patient cluster with a strong treatment response after switching medication. The current analyses should assist in identifying children likely to achieve a favourable treatment course with MPH and, additionally, those who are in need of alternative treatment options.

【 授权许可】

   
2013 Hautmann et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Faraone SV, Buitelaar J: Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010, 19:353-364.
• [2]Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM: Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 2008, 28:783-800.
• [3]Connor DF, Steeber J, McBurnett K: A review of attention-deficit/hyperactivity disorder complicated by symptoms of oppositional defiant disorder or conduct disorder. J Dev Behav Pediatr 2010, 31:427-440.
• [4]Sinzig J, Döpfner M, Lehmkuhl G, German Methylphenidate Study Group: Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007, 17:421-432.
• [5]Abikoff H, Hechtman L, Klein RG, Gallagher R, Fleiss K, Etcovitch J, Cousins L, Greenfield B, Martin D, Pollack S: Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004, 43:820-829.
• [6]Wender PH, Reimherr FW, Marchant BK, Sanford ME, Czajkowski LA, Tomb DA: A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord 2011, 15:36-45.
• [7]Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E: European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011, 20:17-37.
• [8]National Institute for Health and Clinical Excellence: Attention Deficit Hyperactivity Disorder. Diagnosis and Management of ADHD in Children, Young People and Adults. National Clinical Practice Guideline Number 72. http://www.nice.org.uk/nicemedia/live/12061/42060/42060.pdf webcite
• [9]Pliszka S: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007, 46:894-921.
• [10]Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A: European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry 2004, 13(Suppl 1):i7-i30.
• [11]Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management: ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011, 128:1007-1022.
• [12]Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D: Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008, 165:721-730.
• [13]Coghill D: What does it mean? Looking beyond group differences in clinical research. Eur Child Adolesc Psychiatry 2011, 20:537-539.
• [14]Kazdin AE: Evidence-based treatment research: advances, limitations, and next steps. Am Psychol 2011, 66:685-698.
• [15]Ghuman JK, Riddle MA, Vitiello B, Greenhill LL, Chuang SZ, Wigal SB, Kollins SH, Abikoff HB, McCracken JT, Kastelic E, Scharko AM, McGough JJ, Murray DW, Evans L, Swanson JM, Wigal T, Posner K, Cunningham C, Davies M, Skrobala AM: Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol 2007, 17:563-580.
• [16]McLachlan G, Peel D: Finite Mixture Models. New York: Wiley; 2000.
• [17]Vermunt JK: Longitudinal research using mixture models. In Longitudinal research with latent variables. Edited by van Montfort K, Oud JHL, Satorra A. Heidelberg: Springer; 2010:119-152.
• [18]Lubke GH, Muthén B: Investigating population heterogeneity with factor mixture models. Psychol Methods 2005, 10:21-39.
• [19]Nagin DS, Odgers CL: Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 2010, 6:109-138.
• [20]Sonuga-Barke EJ, Van Lier P, Swanson JM, Coghill D, Wigal S, Vandenberghe M, Hatch S: Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder: a growth mixture modelling analysis. Eur Child Adolesc Psychiatry 2008, 17:245-254.
• [21]Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004, 113:e206-e216.
• [22]Swanson JM, Hinshaw SP, Arnold LE, Gibbons RD, Marcus S, Hur K, Jensen PS, Vitiello B, Abikoff HB, Greenhill LL, Hechtman L, Pelham WE, Wells KC, Conners CK, March JS, Elliott GR, Epstein JN, Hoagwood K, Hoza B, Molina BS, Newcorn JH, Severe JB, Wigal T: Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry 2007, 46:1003-1014.
• [23]MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999, 56:1073-1086.
• [24]Daughton JM, Kratochvil CJ: Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009, 48:240-248.
• [25]Ermer JC, Adeyi BA, Pucci ML: Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder. CNS Drugs 2010, 24:1009-1025.
• [26]Wolraich ML, Doffing MA: Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 2004, 18:243-250.
• [27]Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E: Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006, 15:476-495.
• [28]Hosenbocus S, Chahal R: A review of long-acting medications for ADHD in Canada. J Can Acad Child Adolesc Psychiatry 2009, 18:331-339.
• [29]Faraone SV: Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. Proc Natl Acad Sci USA 2009, 34:678-694.
• [30]Shire Pharmaceuticals: Equasym XL SPC. http://www.medicines.org.uk/EMC/medicine/15804/SPC/Equasym+XL+10+mg%2c+20+mg+or+30+mg+Capsules/ webcite
• [31]Anderson VR, Keating GM: Methylphenidate controlled-delivery capsules (Equasym XL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder. Paediatr Drugs 2006, 8:319-333.
• [32]Döpfner M, Görtz-Dorten A, Breuer D, Rothenberger A: An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety. Eur Child Adolesc Psychiatry 2011, 20:S243-S255.
• [33]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington: APA; 2000.
• [34]World Health Organization: International Classification of Diseases (ICD-10). Geneva: WHO; 1992.
• [35]Bundesinstitut für Arzneimittel und Medizinprodukte, Paul-Ehrlich-Institut: Empfehlungen des Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen. http://www.bfarm.de/DE/Arzneimittel/1_vorDerZul/klinPr/nichtInterventPruef/nichtInterventPruef-home.html webcite
• [36]The European Parliament and the Council of the European Union: Directive 2001/20/EC of the European Parliament and the Council of 4 April 2001 on the Approximation of the Laws, Regulations and Administrative Provisions of the Member States Relating to the Implementation of Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Humn Use. http://www.eortc.be/services/doc/clinical-eu-directive-04-april-01.pdf webcite
• [37]Döpfner M, Görtz-Dorten A, Lehmkuhl G: DISYPS-II: Diagnostik-System für psychische Störungen im Kindes- und Jugendalter nach ICD-10 und DSM-IV. Bern: Hans Huber; 2008.
• [38]Goodman R: The Strengths and Difficulties Questionnaire: a research note. J Child Psychol Psychiatry 1997, 38:581-586.
• [39]Muthén B, Shedden K: Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics 1999, 55:463-469.
• [40]Muthén B: Latent variable analysis: growth mixture modeling and related techniques for longitudinal data. In Handbook of quantitative methodology for the social sciences. Edited by Kaplan D. Newbury Park: Sage; 2004:345-368.
• [41]Singer JD, Willett JB: Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York: Oxford University Press; 2003.
• [42]Muthén B: Mplus Technical Appendices. Los Angeles: Muthén & Muthén; 2004.
• [43]Roeder K, Lynch KG, Nagin DS: Modeling uncertainty in latent class membership: a case study in criminology. J Am Stat Assoc 1999, 94:766-776.
• [44]Arbuckle JL: Full information estimation in the presence of incomplete data. In Advanced structural equation modelling: issues and techniques. Edited by Marcoulides GA, Schumacker RE. Mahwah: Lawrence Erlbaum; 1996:243-277.
• [45]Raykov T: Analysis of longitudinal studies with missing data using covariance structure modeling with full-information maximum likelihood. Struct Equation Model 2005, 12:493-505.
• [46]Schwarz G: Estimating the dimension of a model. Ann Stat 1978, 6:461-464.
• [47]Muthén B, Muthén L: Mplus (Version 6.12) [Computer Software]. Los Angeles: Muthén & Muthén; 2011.
• [48]Faraone SV, Biederman J, Mick E: The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006, 36:159-165.
• [49]Waschbusch DA: A meta-analytic examination of comorbid hyperactive-impulsive-attention problems and conduct problems. Psychol Bull 2002, 128:118-150.
• [50]Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, Casas M: Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 2011, 25:157-169.
• [51]Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH: A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003, 112:e404.
• [52]Pelham WE Jr, Fabiano GA: Evidence-based psychosocial treatments for attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol 2008, 37:184-214.
• [53]Young S, Amarasinghe JM: Practitioner review: non-pharmacological treatments for ADHD: a lifespan approach. J Child Psychol Psychiatry 2010, 51:116-133.
• [54]Taylor E, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M: Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med 1987, 17:121-143.
• [55]MTA Cooperative Group: Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder. Arch Gen Psychiatry 1999, 56:1088-1096.
• [56]Owens EB, Hinshaw SP, Kraemer HC, Arnold LE, Abikoff HB, Cantwell DP, Conners CK, Elliott G, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells KC, Wigal T: Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol 2003, 71:540-552.
• [57]Tannock R: ADHD with anxiety disorders. In ADHD comorbidities: Handbook for ADHD complications in children and adults. Edited by Brown TE. Arlington: American Psychiatric Publishing; 2009:131-155.
• [58]Döpfner M, Breuer D, Walter D, Rothenberger A: An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality of life outcomes. Eur Child Adolesc Psych 2011, 20:S277-S288.
• [59]Evidence-Based Medicine Working Group: Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA 1992, 268:2420-2425.
• [60]Montori VM, Guyatt GH: Progress in evidence-based medicine. JAMA 2008, 300:1814-1816.
• [61]Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D: Current methods of the US preventive services task force: a review of the process. Am J Prev Med 2001, 20:21-35.
• [62]Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer TT, Varonen H, Vist GE, Williams JW Jr, Zaza S: Grading quality of evidence and strength of recommendations. BMJ 2004, 328:1490.
• [63]Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000, 342:1887-1892.
• [64]Concato J: Observational versus experimental studies: what's the evidence for a hierarchy? NeuroRx 2004, 1:341-347.
• [65]Collins LM: Analysis of longitudinal data: the integration of theoretical model, temporal design, and statistical model. Annu Rev Psychol 2006, 57:505-528.